Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo

International Journal of Cancer

Volumn 137, Issue 5, 2015, Pages 1047-1057

  Lamour, Virginie ^a   Henry, Aurélie ^a   Kroonen, Jérôme ^a   Nokin, Marie Julie ^a   Von Marschall, Zofia ^b   Fisher, Larry W ^b   Chau, Tieu Lan ^a   Chariot, Alain ^a   Sanson, Marc ^c   Delattre, Jean Yves ^c   Turtoi, Andrei ^a   Peulen, Olivier ^a   Rogister, Bernard ^a   Castronovo, Vincent ^a   Bellahcène, Akeila ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

EGFR; glioblastoma; osteopontin; Sox2; tumor initiating cells

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOPONTIN; PROTEIN KINASE B; S6 KINASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENICITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; BRAIN TUMOR; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; GLIOBLASTOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; AUTOCRINE COMMUNICATION; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE SILENCING; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OSTEOPONTIN; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR;

EID: 84931577559     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29454     Document Type: Article

References (49)

1. Fisher LW, Torchia DA, Fohr B, et al., Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001; 280: 460-5.
2. Bellahcène A, Castronovo V, Ogbureke kU, et al., Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008; 8: 212-26.
3. Cook AC, Tuck AB, McCarthy S, et al., Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog 2005; 43: 225-36.
4. Coppola D, Szabo M, Boulware D, et al., Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184-90.
5. Szabo E,. Selecting targets for cancer prevention: where do we go from here? Nat Rev Cancer 2006; 6: 867-74.
6. Neman J, Jandial R,. Decreasing glioma recurrence through adjuvant cancer stem cell inhibition. Biologics 2010; 4: 157-62.
7. Saitoh Y, Kuratsu J, Takeshima H, et al., Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995; 72: 55-63.
8. Jang T, Savarese T, Low HP, et al., Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol 2006; 168: 1676-85.
9. Gunnersen JM, Spirkoska V, Smith PE, et al., Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia 2000; 32: 146-54.
10. Tucker MA, Chang PL, Prince CW, et al., TPA-mediated regulation of osteopontin in human malignant glioma cells. Anticancer Res 1998; 18: 807-12.
11. Sreekanthreddy P, Srinivasan H, Kumar DM, et al., Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1409-22.
12. Lamour V, Le Mercier M, Lefranc F, et al., Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 2010; 126: 1797-805.
13. Jan HJ, Lee CC, Shih YL, et al., Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 2010; 12: 58-70.
14. Oka M, Tagoku K, Russell TL, et al., CD9 is associated with leukemia inhibitory factor-mediated maintenance of embryonic stem cells. Mol Biol Cell 2002; 13: 1274-81.
15. Botquin V, Hess H, Fuhrmann G, et al., New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2. Genes Dev 1998; 12: 2073-90.
16. Ogata T, Ueyama T, Nomura T, et al., Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3-kinase/akt pathway. Biochem Biophys Res Commun 2007; 359: 341-7.
17. Kilic G, Wang J, Sosa-Pineda B,. Osteopontin is a novel marker of pancreatic ductal tissues and of undifferentiated pancreatic precursors in mice. Dev Dyn 2006; 235: 1659-67.
18. Wai PY, Kuo PC,. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-18.
19. Ahmed M, Behera R, Chakraborty G, et al., Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011; 15: 1113-26.
20. Pietras A, Katz AM, Ekstrom EJ, et al., Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 2014; 14: 357-69.
21. Katz AM, Amankulor NM, Pitter K, et al., Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One 2012; 7: e32453
22. Singh SK, Clarke ID, Terasaki M, et al., Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
23. Singh SK, Hawkins C, Clarke ID, et al., Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
24. Galli R, Binda E, Orfanelli U, et al., Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-21.
25. Yuan X, Curtin J, Xiong Y, et al., Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23: 9392-400.
26. Hemmati HD, Nakano I, Lazareff JA, et al., Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-83.
27. Fong H, Hohenstein KA, Donovan PJ,. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells 2008; 26: 1931-8.
28. Yu SC, Ping YF, Yi L, et al., Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008; 265: 124-34.
29. Bertr J, Begaud-Grimaud G, Bessette B, et al., Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int J Oncol 2009; 34: 717-27.
30. Sunayama J, Matsuda KI, Sato A, et al., Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010; 11: 1930-39.
31. Bikeye SN, Colin C, Marie Y, et al., ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell Int 2010; 10: 1
32. Fedarko NS, Fohr B, Robey PG, et al., Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000; 275: 16666-72.
33. Kroonen J, Nassen J, Boulanger YG, et al., Human glioblastoma-initiating cells invade specifically the subventricular zones and olfactory bulbs of mice after striatal injection. Int J Cancer 2011; 129: 574-85.
34. Anborgh PH, Mutrie JC, Tuck AB, et al., Role of the metastasis-promoting protein osteopontin in the tumor microenvironment. J Cell Mol Med 2010; 8: 2037-44.
35. Gangemi RM, Griffero F, Marubbi D, et al., SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27: 40-8.
36. Xiang R, Liao D, Cheng T, et al., Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 2011; 104: 1931
37. Fan QW, Weiss WA,. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 2010; 347: 279-96.
38. Zhou J, Wulfkuhle J, Zhang H, et al., Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007; 104: 16158-63.
39. Goffart N, Kroonen J, Rogister B,. Glioblastoma-initiating cells: relationship with neural stem cells and the micro-environment. Cancers 2013; 5: 1049-71.
40. Bonnert TP, Bilsl JG, Guest PC, et al., Molecular characterization of adult mouse subventricular zone progenitor cells during the onset of differentiation. Eur J Neurosci 2006; 24: 661-75.
41. Jijiwa M, Demir H, Gupta S, et al., CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011; 6: e24217
42. Cooper LA, Gutman DA, Long Q, et al., The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010; 5: e12548
43. Zhou BB, Zhang H, Damelin M, et al., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-23.
44. Eyler CE, Foo WC, LaFiura KM, et al., Brain cancer stem cells display preferential sensitivity to akt inhibition. Stem Cells 2008; 26: 3027-36.
45. Sunayama J, Sato A, Matsuda K, et al., Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 2010; 12: 1205-19.
46. Nakamura JL, Garcia E, Pieper RO,. S6K1 plays a key role in glial transformation. Cancer Res 2008; 68: 6516-23.
47. Tsatas D, Kanagasundaram V, Kaye A, et al., EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci 2002; 9: 282-8.
48. Hu Q, Zhang L, Wen J, et al., The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells. Stem Cells 2010; 28: 279-86.
49. Takaishi S, Okumura T, Tu S, et al., Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-20.